PMID- 36059644
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220907
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in 
      nasopharyngeal carcinoma.
PG  - 953884
LID - 10.3389/fonc.2022.953884 [doi]
LID - 953884
AB  - Antibodies targeting the programmed cell death protein-1 (PD-1) molecule have 
      been reported to hold promising antitumor activities in patients with 
      nasopharyngeal carcinoma (NPC). However, only a small subset of NPC patients 
      benefits from the anti-PD-1 monotherapy and factors that affect the treatment 
      response need further investigation. This study aimed to examine the impact of 
      multiple genetic and environmental factors on outcome of anti-PD-1 immunotherapy 
      by identifying tumor size, tumor mutation burden (TMB) based on whole exon 
      sequencing, human leukocyte antigen class I (HLA-I) homo-/heterozygosity and 
      supertypes, blood Epstein-Barr virus (EBV) DNA load, T cell proportions, and 
      interferon-gamma(IFN-gamma) levels in a cohort of 57 NPC patients that received Nivolumab 
      or Camrelizumab treatment. Moreover, we profiled the longitudinal changes in gut 
      microbiota composition using shotgun metagenomics sequencing. We observed that 
      high TMB combined with HLA-I heterozygosity was associated with improved clinical 
      outcomes. In agreement with previous studies, we found that patients with higher 
      plasma EBV DNA load showed worse progression-free survival. We found no evidence 
      for an effect of gut bacterial diversity on the treatment response, but 
      identified a higher abundance of seven specific gut bacteria at baseline of 
      non-responders, including Blautia wexlera and Blautia obeum, as well as four 
      other bacteria belonging to the Clostridiales order, and one 
      Erysipelatoclostridium. Combined, this study provides insight into the influence 
      of several genetic and environmental factors on anti-PD-1 immunotherapy responses 
      in NPC patients.
CI  - Copyright (c) 2022 Xu, Ma, Fang, Peng, Gao, Moll, Qin, Yu, Hou, Kristiansen, Fang, 
      Brix and Zhang.
FAU - Xu, Liqin
AU  - Xu L
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - Department of Biotechnology and Biomedicine, Technical University of Denmark, 
      Kgs. Lyngby, Denmark.
AD  - Latvia MGI Tech SIA, Marupe, Latvia.
FAU - Ma, Yuxiang
AU  - Ma Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Fang, Chao
AU  - Fang C
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - China National GeneBank, BGI-Shenzhen, Shenzhen, China.
AD  - Laboratory of Genomics and Molecular Biomedicine, Department of Biology, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Peng, Zhuobing
AU  - Peng Z
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - China National GeneBank, BGI-Shenzhen, Shenzhen, China.
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Gao, Fangfang
AU  - Gao F
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Moll, Janne Marie
AU  - Moll JM
AD  - Department of Biotechnology and Biomedicine, Technical University of Denmark, 
      Kgs. Lyngby, Denmark.
FAU - Qin, Shishang
AU  - Qin S
AD  - BGI-Shenzhen, Shenzhen, China.
FAU - Yu, Qichao
AU  - Yu Q
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - China National GeneBank, BGI-Shenzhen, Shenzhen, China.
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Hou, Yong
AU  - Hou Y
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - Latvia MGI Tech SIA, Marupe, Latvia.
AD  - China National GeneBank, BGI-Shenzhen, Shenzhen, China.
FAU - Kristiansen, Karsten
AU  - Kristiansen K
AD  - BGI-Shenzhen, Shenzhen, China.
AD  - Laboratory of Genomics and Molecular Biomedicine, Department of Biology, 
      University of Copenhagen, Copenhagen, Denmark.
AD  - Institute of Metagenomics, Qingdao-Europe Advanced Institute for Life Sciences, 
      Qingdao, China.
FAU - Fang, Wenfeng
AU  - Fang W
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Brix, Susanne
AU  - Brix S
AD  - Department of Biotechnology and Biomedicine, Technical University of Denmark, 
      Kgs. Lyngby, Denmark.
AD  - Institute of Metagenomics, Qingdao-Europe Advanced Institute for Life Sciences, 
      Qingdao, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220817
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9428750
OTO - NOTNLM
OT  - EBV
OT  - HLA
OT  - NPC
OT  - PD-1
OT  - TMB
OT  - gut microbiota
OT  - immunotherapy
COIS- The author's LX and YH were employed by the company Latvia MGI Tech SIA. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/06 06:00
MHDA- 2022/09/06 06:01
PMCR- 2022/01/01
CRDT- 2022/09/05 03:40
PHST- 2022/05/26 00:00 [received]
PHST- 2022/07/27 00:00 [accepted]
PHST- 2022/09/05 03:40 [entrez]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/06 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.953884 [doi]
PST - epublish
SO  - Front Oncol. 2022 Aug 17;12:953884. doi: 10.3389/fonc.2022.953884. eCollection 
      2022.